{
    "ticker": "MNKD",
    "name": "MannKind Corporation",
    "description": "MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of innovative inhaled therapeutic products for the treatment of diabetes and other serious conditions. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind is best known for its flagship product, Afrezza, an inhaled insulin powder that offers a unique delivery method for people with diabetes. This groundbreaking treatment allows for rapid absorption and provides patients with a more convenient alternative to traditional insulin injections. The company is committed to improving the lives of those with diabetes through its cutting-edge technology and research. MannKind is also exploring other therapeutic areas, including pulmonary diseases, by utilizing its proprietary Technosphere\u00ae technology, which enhances drug delivery via inhalation. The company is dedicated to advancing its product pipeline and has collaborations aimed at expanding its market reach. With a strong emphasis on innovation and patient-centric solutions, MannKind aims to address the unmet needs of patients who require effective and convenient treatment options.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Danbury, Connecticut, USA",
    "founded": "1991",
    "website": "https://www.mannkindcorp.com",
    "ceo": "Michael Castagna",
    "social_media": {
        "twitter": "https://twitter.com/mannkindcorp",
        "linkedin": "https://www.linkedin.com/company/mannkind-corporation/"
    },
    "investor_relations": "https://investors.mannkindcorp.com",
    "key_executives": [
        {
            "name": "Michael Castagna",
            "position": "CEO"
        },
        {
            "name": "Cheryl Blanchard",
            "position": "President and Chief Operating Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Diabetes Treatments",
            "products": [
                "Afrezza"
            ]
        },
        {
            "category": "Pulmonary Therapeutics",
            "products": [
                "Technosphere\u00ae Technology"
            ]
        }
    ],
    "seo": {
        "meta_title": "MannKind Corporation | Innovative Inhaled Diabetes Treatments",
        "meta_description": "MannKind Corporation is a biopharmaceutical company dedicated to improving diabetes treatment with innovative inhaled therapies. Discover Afrezza and our commitment to patient care.",
        "keywords": [
            "MannKind",
            "Diabetes",
            "Inhaled Insulin",
            "Afrezza",
            "Biopharmaceuticals",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What is MannKind known for?",
            "answer": "MannKind is known for its innovative inhaled insulin product, Afrezza, designed for people with diabetes."
        },
        {
            "question": "Who is the CEO of MannKind?",
            "answer": "Michael Castagna is the CEO of MannKind Corporation."
        },
        {
            "question": "Where is MannKind headquartered?",
            "answer": "MannKind is headquartered in Danbury, Connecticut, USA."
        },
        {
            "question": "What are MannKind's main products?",
            "answer": "MannKind's main product is Afrezza, an inhaled insulin, and they also develop therapies using Technosphere\u00ae Technology."
        },
        {
            "question": "When was MannKind founded?",
            "answer": "MannKind was founded in 1991."
        }
    ],
    "competitors": [
        "PFE",
        "SNY",
        "NVO",
        "LLY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BIIB"
    ]
}